The FDA and Stem Cell Clinics: Why Some Are Legal and Some Are Not
Asare B. Christian, MD, MPH · 2026-11-21
Direct Answer
Cell therapies are regulated as biological drugs. A narrow exception permits same-day, minimally manipulated, same-patient use for the tissue's normal function. Clinics that culture cells, use donor cells, add growth factors, or make claims about treating disease cross into unapproved drug territory, regardless of how they describe themselves.
The Framework in Plain Language
Under 21 CFR Part 1271, human cells and tissues intended for implantation are regulated as drugs, devices, or biological products unless they meet specific exceptions.
Two criteria define the main exception. The cells must be minimally manipulated, meaning processing that does not alter their biological characteristics. And they must be intended for homologous use, meaning the same basic function in the recipient as in the donor.
A third practical element: same surgical procedure, meaning tissue removed and reimplanted in the same patient during the same operation.
Bone marrow aspirate used during an orthopedic procedure, concentrated and reinjected into a joint or tendon site, is the classic case that arguably fits. Culturing cells for three weeks to expand the count, adding growth factors, or using umbilical cord cells from a donor does not fit.
Where Clinics Push Past the Line
Marketing language is one signal. A clinic advertising treatment of Parkinson's disease, multiple sclerosis, autism, or "anti-aging" with an injection is making disease claims, which is incompatible with the exception.
Intravenous administration of cells for systemic indications is another signal, because a joint-derived mesenchymal cell is not performing its normal function when infused into a vein.
Combining cell injections with unapproved additives, or shipping culture-expanded cells across state lines, adds further exposure.
What Enforcement Looks Like
The FDA has issued numerous warning letters, obtained injunctions, and pursued litigation. In 2019, a federal court ruled against two Florida clinics, holding that their adipose-derived cell products were unapproved drugs, in one case with a finding that the products were also adulterated. Subsequent enforcement has continued, with particular attention to products claiming to treat serious diseases and to those involving spinal injection.
State laws complicate the picture. Some states have passed legislation permitting clinics to offer unapproved therapies with patient consent. Those laws do not change the FDA's federal authority, and patients should understand that state permission is not federal approval.
The Insurance and Liability Angle
Unapproved therapies are generally not covered by insurance, and complications may fall entirely on the patient. If something goes wrong during an unapproved procedure, the clinic's legal position is often less stable than its marketing suggests, which can matter when a patient is seeking remedy.
Questions That Separate the Categories
Ask what the product is: cells, or something else. Ask where the cells come from: this patient, today, or a donor through a lab. Ask what processing occurred: concentration only, or culture expansion. Ask whether the clinic operates under an investigational new drug application, and if so, get the IND number.
Ask for the written consent document and read what it says about regulatory status. Ask how they measure cell count and viability, and what their serious adverse event rate has been.
A clinic operating within the exception can answer these clearly and without defensiveness. A clinic operating outside it usually cannot, and often reframes the questions as hostility.
Where This Leaves Legitimate Practice
A physician-led practice can offer regenerative procedures within the exception, with honest disclosure that the intervention is not FDA approved for the indication, that evidence is limited, and that cost is borne by the patient. That is a defensible position.
What is not defensible is ambiguity designed to let a patient assume approval exists, or claims that the therapy treats conditions for which there is no evidence.
Limitations
The regulatory boundary depends on facts that vary case by case, including the exact processing steps and the intended use. This article describes the framework and does not constitute legal advice. Enforcement priorities also shift between administrations, and the number of clinics operating unapproved has grown faster than enforcement capacity.
Frequently Asked Questions
Is PRP regulated the same way? PRP is generally regulated differently, as it involves minimal manipulation of blood rather than cells for implantation, though its marketing claims remain subject to FDA and FTC oversight.
Are umbilical cord stem cell injections legal? Products from donor tissue, particularly culture-expanded or systemically infused, are generally unapproved drugs unless used under an IND or an approved application.
What happens if a clinic is shut down? Patients lose access to follow-up, records can be difficult to obtain, and complications may be left unmanaged.
Does FDA approval exist for any orthopedic cell therapy? Not for arthritis, tendon injury, or spinal pain. Approved cell therapies exist in hematology and a limited number of other indications.
References
- FDA. Regulatory considerations for human cells, tissues, and cellular and tissue-based products. Guidance documents.
- 21 CFR Part 1271.
- United States v. U.S. Stem Cell Clinic, LLC, federal court ruling, 2019.
- FDA warning letters and enforcement actions involving unapproved cell therapy, 2019 to 2025.
Educational information only. This is a draft for physician review and is not individualized medical advice.